Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Relapsed B-cell NHL
NCT05615636Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Apr 2023
- Primary completion
- Aug 2027
- Modality
- Small Molecules, Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label trial of mosunetuzumab, polatuzumab vedotin, tafasitamab and lenalidomide in follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Safety of mosunetuzumab, polatuzumab vedotin, tafasitamab, and lenalidomide and Best Overall Response Rate. Started Apr 2023; status: recruiting.
02
Drugs
mosunetuzumabpolatuzumab vedotintafasitamablenalidomide
03
Conditions
follicular lymphoma (FL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05615636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05615636.